The trial of new made in Russia thrombolytic Fortelyzin in patients with acute myocardial infarction
Автор: Markin S.S., Semenov A.M., Markov V.A., Vyshlov E.V., Nizov A.A., Aksentyev S.B., Ponomarev E.A., Lebedev P.A., Barbarash O.L., Kashtalap V.V.
Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk
Рубрика: Клинические исследования
Статья в выпуске: 1 т.27, 2012 года.
Бесплатный доступ
Fortelyzin is a new thrombolytic, which represents a genemodified staphylokinase. The present clinical trial showed that Fortelyzin and Actilyse are comparative effective thrombolytics estimating reperfusion in patients with acute myocardial infarction according to TIMI grade. In the Actilyse patients group the fibrinogen level decreased more intensively then in Fortelyzin group. The safety was similar in both groups.
Fibrinselective thrombolytic, safety, patients with acute myocardial infarction, fortelyzin, actilyse, efficacy
Короткий адрес: https://sciup.org/14919695
IDR: 14919695
